)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics (BCLI) investor relations material
Brainstorm Cell Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary31 Mar, 2026
Executive summary
Advanced NurOwn into a Phase 3b confirmatory study for ALS after FDA clearance in May 2025, aiming for BLA submission if successful.
Secured $2 million in strategic financing post year-end, supporting operational activities and resulting in a significant share re-rating.
Durable long-term survival observed in Expanded Access Program cohort, supporting focus on earlier-stage ALS populations in upcoming trials.
Financial highlights
Cash, cash equivalents, and restricted cash were $0.3 million as of December 31, 2025; $2 million in new funding secured in early 2026.
Research and development expenses for 2025 were $4.2 million, down from $4.7 million in 2024.
General and administrative expenses were $5.8 million in 2025, compared to $7.0 million in 2024.
Net loss for 2025 was $10.3 million, improved from $11.6 million in 2024.
Net loss per share was $1.11 in 2025, compared to $2.31 in 2024.
Outlook and guidance
Phase 3b ENDURANCE trial of NurOwn is set to enroll approximately 200 participants, with a two-part design to assess efficacy and long-term safety.
Strategic financing provides cash runway to execute key operational activities and preparatory work for the planned trial.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Brainstorm Cell Therapeutics
- Phase III-B ALS trial advances with FDA alignment, CRO engagement, and new financing secured.BCLI
Status Update3 Feb 2026 - Q2 2024 featured lower net loss, regulatory milestones, and $4M in new funding amid Nasdaq risks.BCLIQ2 20241 Feb 2026
- NurOwn's new phase III-B trial targets early ALS with promising efficacy and biomarker results.BCLIStatus Update11 Jan 2026
- Phase 3B ALS trial on track for Q1 2025, with strong FDA alignment and funding progress.BCLIStatus Update10 Jan 2026
- Net loss narrowed, funding secured, and pivotal ALS trial preparations advanced amid financial risks.BCLIQ4 202426 Dec 2025
- Shelf registration for $172.6M in securities; $5.8M at-the-market offering via Raymond James.BCLIRegistration Filing16 Dec 2025
- Up to 16.7M shares registered for resale from warrants, with proceeds supporting operations.BCLIRegistration Filing16 Dec 2025
- Registering 2.76M shares for resale, with proceeds from warrant exercises funding operations.BCLIRegistration Filing16 Dec 2025
- Registering 16.7M shares for resale, with warrant proceeds to fund operations amid Nasdaq risks.BCLIRegistration Filing16 Dec 2025
Next Brainstorm Cell Therapeutics earnings date
Q1 202618 May, 2026
Brainstorm Cell Therapeutics
Next Brainstorm Cell Therapeutics earnings date
Q1 202618 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage